Effect of sodium-glucose cotransporter 2 inhibitors (SGLT2) on the occurrence of tachyarrhythmias in patients with heart failure with reduced ejection fraction

12 April 2026 (08:00 - 15:30)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Juan Jose Serrano Silva

General Hospital of Jerez, Jerez de la Frontera (Spain)

5 More presentations in this session

Presentation thumbnail

Results of a national survey on ethacizine for atrial fibrillation treatment in real practice as a part of a patient oriented approach

Professor N. Sydorova (Kiev, UA)

Abstract Slides Video

Presentation thumbnail

The influence of digoxin on outcomes in remotely monitored patients with implantable cardioverter-defibrillators

Doctor M. Dyrbus (Zabrze, PL)

Abstract Slides Video

Presentation thumbnail

Flecainide in the treatment of high premature ventricular contractions burden: preliminary results from the UNIFLECA study

Doctor S. Kotoulas (Athens, GR)

Abstract Slides Video

Presentation thumbnail

Can colchicine tame atrial fibrillation? A scoping review

Miss S. Hasan (Coventry, GB)

Abstract Slides Video

Presentation thumbnail

Comparative outcomes of amiodarone and dronedarone in atrial fibrillation: a real-world retrospective cohort study

Doctor A. Akuka (Holon, IL)

Abstract Slides Video

Access the full session

Session thumbnail

Antiarrhythmic drugs

The Event

Event poster

EHRA 2026

12 April - 14 April 2026

You may be interested in

Congress Presentation

Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomised controlled trials

Congress Session

Further Insights into SGLT2i treatment for heart failure

Congress Session

Young Investigator Award (YIA) Clinical Cardiology

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources